Some, as you say "skittish" investors are selling

Some, as you say "skittish" investors are selling because they see compounding and the insurance provider's decision as the end all to SCRC's success. It's probably the best decision for these investors. They never had a grasp on SCRC's potential.

From what Mr. Schneiderman stated in his summary, is the vary reason I am holding all my shares, as we used to say locked in my desk drawer. Diversification is the strength behind SCRC today, not compounding. Don't get me wrong, compounding will always be a vital part of SCRC's revenue stream and by adding two additional pharmacies (and I bet more on the way) I see the volume of Rxs and revenues to equal and grow beyond what have seen with MAV alone. Plus, PIMD recorded $554K in February and has expanded to supplying services into 16 States. I bet if you look back at Bergen Brunswick, McKession, & Cardinal wholesalers they all started off small. Today each of these wholesalers are worth $billions$. The Diabetes Program recorded $103K in revenues in one month. Patient enrollment and revenues will continue to grow. The pending Physician Dispensing Program has revenue potential beyond anyone's imagination. Finally, RapiMeds potential will eventually prove to be an important contributor to the bottom line.

Diversification is the key to ultimate success, and SCRC is diversified and my guess would be will continue to expand it's business model.